The evaluation of iolgia markers is recoied as necsry to the future oftokcOy , epideniology, and q Iive risk assment. For bio cl nmrkes to becm widely accepted, their validity must be ascertained. This paper explores the range ofconsiderations that compose the concept of validiBt as it applies to the evaluation of bioogical markers. Three broad categories of validity (meaem ent, internal study, and external) are discussed in the context of evWaluating data for use inquantitative risk at. Frticular attention is given to the importnce ofmeuement validity in the consideration ofwhether to use biological markers in epidemiologic studies. The Three broad categories of validity can be distinguished: measurement validity, internal study validity, and external validity. Measurement validity has been defined as an expression ofthe degree to which ".. . a measurement measures what it purports to measure" (9). Internal study validity is the degree to which inferences drawn from a sample are warranted when account is taken of the study methods, the representativeness of the study sample, and the nature ofthe population from which the sample is drawn (9). External study validity is the extent to which the findings of a study can be generalized to other populations (9). likely that the risk assessments constructed from those measurements will also be invalid. Measurement validity characterizes the extent to which a marker ofa phenomenon has content validity (i.e., pertains to the underlying phenomenon); construct validity (i.e., correlates with other relevant characteristics of the underlying phenomenon); and criterion validity (i.e., predicts some component of the underlying phenomenon). In general, these three components ofmeasurement validity are best assessed in terms of the extent or degree to which they apply to the underlying phenomenon, rather than as an all-or-none condition (JO).
Introduction
It is generally accepted that valid biological markers can make an important contribution to toxicologic and epidemiologic research, and ultimately, to quantitative risk assessment (1) (2) (3) . While obeisance is paid to the concept ofvalidity, little attention has been given to what it means and how to evaluate it. The objective ofthis paper is to identify and explore the range ofthe concept ofvalidity and to address how considerations that comprise the concept ofvalidity and to address how validity pertains to the use of biological markers in quantitative risk assessment. The term "biological marker" has been defined as an indicator that signals events in biological systems or samples, and it is generally taken to be any biochemical, genetic, or immunologic indicator that can be measured in a biological specimen (4) (5) (6) (7) . Ascribed to the term biological marker is its role as an indicator ofevents in a continuum between exposure to a xenobiotic substance and resultant disease (4, 6) . Biologic markers can refer to any ofthree categories of events: exposure, effect, and susceptibility. Unless otherwise specified, in this discussion, a marker is considered to relate to an event in the exposure-disease continuum without further reference as to whether that event is exposure, effect, or susceptibility. Biological markers can contribute to quantitative risk assessment by helping to: determine the forms ofdose-timeresponse relationships; assess the biologically effective dose; make interspecies comparison ofeffective dose, relative potency, and effects; resolve the quantitative relationships between human interindividual variability in susceptibility; and identify subpopulations that are at enhanced risk (2, 8 Three broad categories of validity can be distinguished: measurement validity, internal study validity, and external validity. Measurement validity has been defined as an expression ofthe degree to which ".. . a measurement measures what it purports to measure" (9) . Internal study validity is the degree to which inferences drawn from a sample are warranted when account is taken of the study methods, the representativeness of the study sample, and the nature ofthe population from which the sample is drawn (9) . External study validity is the extent to which the findings of a study can be generalized to other populations (9) .
Biological markers and the studies that include them need to be shown to have measurement, internal, and external validity before they can be accurately used in quantitative risk assessment. The use of invalid markers can result in nondifferential misclassifications of exposure or outcome, which can lead to under estimation ofa true effect (3) . Risk assessments based on studies that underestimate a true effect can lead to regulations that contain exposure limits thought to be safe but, in fact, are not. Conversely, a differential misclassification bias, depending on the direction of the bias, can lead to regulations containing exposure limits that are either too high or too low. In quantitative risk assessment, the inferences derived from small study groups are generalized to larger populations. The strength of those inferences depend on the methodology ofthe study, including the measurements and other design factors that lead to the results. Invalid measurements, inferences, or generalizations may lead to erroneous risk assessments. In this paper, the three categories ofvalidity are discussed in terms ofhow they apply to biological markers for research and quantitative risk assessment. These theoretical considerations ofvalidity are illustrated by examples of risk assessments involving ethylene dibromide and ethylene oxide.
Measurement Validity
Measurements are one of the principal building blocks of quantitative risk assessment. If measurements are invalid, it is likely that the risk assessments constructed from those measurements will also be invalid. Measurement validity characterizes the extent to which a marker ofa phenomenon has content validity (i.e., pertains to the underlying phenomenon); construct validity (i.e., correlates with other relevant characteristics of the underlying phenomenon); and criterion validity (i.e., predicts some component of the underlying phenomenon). In general, these three components ofmeasurement validity are best assessed in terms of the extent or degree to which they apply to the underlying phenomenon, rather than as an all-or-none condition (JO).
Content Validity
Content validity is the extent to which a marker "incorporates the domain ofthe phenomenon under study" (9) . For 
Construct Validity
Construct validity describes the extent to which a marker corresponds to other relevant characteristics of the underlying phenomenon, that is, the theoretical concepts or constructs concerning the phenomenon under study (9) . This correspondence is exhibited in partby association ofthe subject marker with other markers or variables of the phenomenon (12, 13) . For example, ifthe characteristics ofa phenomenon change with age, a marker with construct validity will change accordingly (9) . Furthermore, ifthere are no associations with other variables that would reasonably be expected to be linked with the phenomenon under study, then the marker may be of questionable relevance in a study or subsequent risk assessment.
Construct validity is sometimes difficult to distinguish from content validity when describing biological markers, but it should be evaluated whenever general understanding of the underlying phenomenon is not clear. Hence, ifa marker is a candidate for inclusion in a study ofan exposure or outcome, and the actal role ofthe marker in the exposure-outcome continuum has not been established (that is, its content validity has not been established), it still may be useful as a covariate ifit can be shown to have construct validity.
Criterion Validity
Criterion validity describes the extent to which a marker correlates with the phenomenon being studied (9) . For example, the criterion validity ofa marker ofdisease is the extent to which people who have the marker already have or will develop the disease.
The criterion is what is being marked or indicated by the marker; generally this is a disease, but it could also be an exposure.
1\o aspects ofcriterion validity have been distinguished, concurrent validity and predictive validity (9) . When a marker and its criterion refer to the same point in time, they have concurrent validity. For example, a biological marker ofexposure, such as a hemoglobin adduct, is validated against a determination of a DNA adduct in a target organ (ifthey occur simultaneously). Por markers of exposure, concurrent validity is satisfied by understanding the stoichiometric relationship between the exposure and the internal or biologically effective dose. For markers ofeflfct, concurrent validity is satisfied by a strong correlation between the marker and the disease or dysfuion ofinterest. Concurrent validity is usually determined in crosssectional studies.
Predictive validity refers to a marker's ability to predict the criterion (9) . For example, a marker of altered structure and function, such as abnormal sputum cytology, could be validated against subsequent diagnostic confirmation of lung cancer. Predictive validation requires obtaining samples of subjects, VALDAI7ON OFBIOMARKERS FOR QUANTITATIVERISKASSESSMENT measuring some marker, waiting the necessary time for the effect (criterion) to occur, then assessing the observed correlation (10, 14) . Other factors to consider in predictive validation might include intervening or modifying characteristics that could influence the occurrence ofthe end point and stochastic effects in the development ofthe outcome criterion. In general, the degree ofpredictive validity depends on the extent ofthe correlation between the marker and the criterion. Predictive validity applies to markers of exposure, effect, or susceptibility.
Predictive validation is performed using a longitudinal (prospective) study design. Since one ofthe drawbacks in assessing predictive validity is the potentially long time course necessary for the development of the criterion, there are time-compressing study designs that are useful. One is the contemporaneous casecontrol design and another is the retrospective case-control design; both are limited in their ability to assess marker validity.
A contemporaneous case-control design involves obtaining samples of individuals with and without the criterion of interest (i.e., a disease) then assessing those individuals for the presence ofa marker. The spective case-control design involves selecting individuals with and without a disease (the criterion) and then attempting to identify marker status prior to the appearance of the disease or study end date. Clearly, these approaches are limited. A contemporaneous case-control study, using markers of exposure, will not provide an unambiguous answer concerning predictability if it is difficult to tell whether the marker predicts the criterion disease or is merely the result of it. The retrospective case-control study is difficult to perform because it is not easy to find historic infonnation on the presence ofmany markers.
It is possible tojudge the criterion validity ofa marker in terms of its sensitivity, specificity, and predictive value. Griffith et al. (15) have distinguished the terms sensitivity and specificity as they-refer to laboratory methods to detect a marker and as they are used to describe the ability ofa marker to detect an exposure or to detect or predict an event in a population:
Laborayory sedtvttnrderea methersabiityofadetection system to respond inthe preseneof the marker. Ppuationsenstvty, mconrba, is theSo ofnumn ofsubjects positive for both the marker and the event to the number of subjects with the event.
Laboratory specificity refers to the detection system's ability to fail to respond in the absence ofthe marker. Pbplation specificity is the ratio ofthe number of subjects that are negative fbr both the marker and the event, tothenumberofsubjectsthat are negative forthe event (15) . Griffith et al. also identified two study designs that are useful for determining population sensitivity and specificity (15): The first is based on two independent samples of fixed size. In this design, the health status or exposure status of each subject is ascertined and observations are collected until the pre-set sample sizes are reached in each group. Neither the marker frequency nor the disease frequency play a role. The data might be collected as subjects are identified or in a case-control study from medical records. Also, archived biological samples might be used. The second approach is to select a single sample offixed size from the population ofinterest, and to distribute the subjects into a four-fold table according to the presence or absence of the marker, and the presence or absence ofthe exposure or disease. Sensitivity is then estimated as the ratio ofthe number of subjects positive for both the marker and the disease to the number of subjects with the disease. Specificity is estimated is the ratio of subjects negative for both the marker and the disease to the subjects negative for the disease.
The best way of appraising criterion validity is to compare a marker with a criterion selected as the true characteristic or as the "gold standard" (12, 16) . This is exemplified by efforts to determine the validity of a new procedure for determining whether malignant or premaignant bladder cells can be by assessing DNA hyperploidy (17) . If DNA hyperploidy is a valid marker ofbladder cancer, hyperploidy should occur prior to visible morphological change, which is routinely evaluated by Papanicolaou cytology. Therefore, appropriate validation ofthe marker is not against the cytology, but against a positive bladder biopsy (the gold stndard) some time in the future.
In epidemiologic studies, markers that are invalid measures of a phenomenon can result in misclassification ofexposure, effect, or susceptibility. As Hogue and Brewster (3) observed, "An exposure variable may be misclassified ifthe marker ofexposure has a sensitivity or specificity less than 1.0. That is, someone who is truly exposed is classified as being not exposed, or someone who is truly not exposed is classified as being exposed." If, for example, a marker of biologically effective dose is the basis for exposure classification, misclassification will occur if that marker does not correspond to the actual amount of xenobiotic that interacts with critical macromolecules. This could occur with certain DNA adducts ifthe amount that persists is affected by the repair rtes and if the repair rate varies among individuals.
In summary, the quality of risk assessments depends on the quality and validity of measurements. As Matamoski (18) 
Reliability
Marker validity is also dependant on reliability; that is,, the degree to which a marker will be a valid representative orpredictor ofan event is influenced by the reliability witi which it can be measured. Reliability encompasses de unsystnatic, random variation observed upon repeated measurements (9, 22) . In the measurement of continuous variables, such as with most biological m s, errors ofvarious kinds are inevitable, and the absolutely correct measurement never can be determined (20) .
If a measure of a biological marker yields results that differ markedly from one occasion to another, it is of little value in research or quantitative risk assessment.
Itis possible to use quantitative indices of the extent ofrandom variation of a biologicalmarker. These indices can be used to determine whether the reliability ofa given measure is sufficient for the purpose being considered. Thetwo most comnonindices are the standard error of the measurement and the reliability coefficient (20) . To assess random errors, multiple measurements are needed to compensate for thefact that the random error in the arithmetic mean of several measurements islikely to be much less than the random error in an individual measurement (20) . In most epidemiologic research using biologic markers, there are seldom large numbers of individual values. Thus, only a small number of individuals can be used as a sample of the infinitely larger population to which the distribution refers. The sundard error indicates how the mean of that sample is distributed around the mean of the larger population.
Hence, the standard error of the mean reflects the reliability of the sample mean as an indicator of the population mean (20) . This may not be as informative as the reliability coefficient for evaluating markers to be used in risk assessments. The reliability coefficient is technically known as the intraclass coefficient of variability (21) and ranges from 0 to 1. If each measurement is identical, then the intraclass coefficient is 1.0. The greater the variation between measurements, the less the reliability. Fleiss (21) has evaluated the impact of unsystematic variation in measurement, described the untoward consequences unreliability, and recommended how unreliability can be controlled. The untoward consequences described by Fleiss include: the need to increase sample sizes to overcome unreliability; the systematic biased reduction of correlations between a health measure and the measured extent ofexposure to an environmental risk factor; and high rates ofmisclassification in case-control studies ofthe association between exposure and disease (20) . All ofthese pertain to studies using biologic markers ofexposure or effect. Fleiss (21) recommends that unreliability becontrolledby conducting pilot studies and replicating measurement procedures on each study subject. In some cases the measurement of the amount of a marker is not an end in itself but is used to calculate someothervalue, therebypropagatingmeasurementerrors (20) . Sincecorrectvaluesfrommeasurementsaregenerally neverknown, calculations will, perforce, involveerrors. Thus, it isusefultoknowhowerrorsinindividualmeasurementsaffectthe resultsof subsequent calculations (20) . For example, individual errors in a sum or difference of measurements are added and standard errors are combined with the root sum ofsquares (20) .
Acknowledgment of these calculation errors should be included in studies and subsequent risk assessments. When such errors become significant, appropriate adjustments should be made.
Internal Study Validity
Another building block ofquantitative risk assessment is the study from which inferences about the association between exposure and effect are drawn. Last (9) has defined the intenal validity ofa study as the degree to which index and comparison groups are selected and compared so that, apart from sampling errors, the observed d ;iffrnce between the dependent variables are attributed only to the hypothesized effect. This is validity in the estimation ofeffect, and it is dependent on the ability to control bias. Internal study validity has been widely discussed in epidemiological textbooks. Hence, in this section we will discuss someissuesofinternalvaliditythatpertaintotheuseofbiological markers. Someoftiisdiscussionisspecificiormarkers Hence, the serum PCB concentrations, derived from a sample ofsubjects, was used as a biologic marker to construct a more accurate estimate ofthe true exposure than was available using job classification data.
Analytical Adjustment for Other Variables
When there are multiple variables to be considered in a study, proper data analysis depends on the choice of the correct mathematical model. The strongest models take into account a priori hypotheses specific to the topic under study. The incorporation ofbiologic markers in study designs and mathematical models also implies an understanding of the direction and mechanism ofaction. Additionally, by controlling measurement validity, it is also possible to partially control study validity, as measurement errors can produce biased estimates ofregression coefficients used in models (25) .
Longitudinal studies that employ biological markers will find increasing use in quantitative risk assessments. The validity of those study results will depend, in part, on the analytical approach selected. Such studies may involve repeated measures of a continuous random variable. Thus, there may be measurement errors that are considered random between persons, but which are autocorrelated within persons. The use of autoregressive modeling for the analysis oflongitudinal data by epidemiologists is increasing and is likely to be used more frequently in studies involving biological markers. These models allow for the treatment of the time course of change of a variable (26) . Other methods for analyzing repetitive measures that assume a Gaussian error structure have been reviewed by Louis (25) , who concluded that this area needs continued statistical, numerical, and interpretive research and development.
External Validity
Risk assessment is an effort to address a condition of incomplete data (27) . Hence, risk assessment involves the extrapolation (or generalization) from known exposure-response data to Hi-defined risk situations in target populations. External validity is the degree to which a study can produce unbiased inferences about those target populations. For risk assessment, external validity involves the appropriateness of extrapolating between populations or species; from high doses to low doses; and between different organs within a species. All of these efforts can be enhanced by using biologic markers common to each population or species. Allometric assessments of effects in different species can be determined by observing how the same marker varies with similar exposures. Valid extrapolation requires an understanding ofthe major events that can cause such inter-and intraspecies differences. For example, in chemical carcinogenesis, the following factors appear to play a critical role in species and organ differences: the overall balance of metabolic activation and detoxification; the balance ofDNA damage and repair; the persistence of DNA damage; and tumor formation (28) .
There are many uncertainties attendant to extrapolating to a large population from data derived from an epidemiologic study ofa smaller group. The characteristics that make a study internally valid are often barriers to extrapolation. Extrapolation is, nevertheless, current practice in risk assessment. Using valid biological markers may allow some evaluation ofwhether a particular extrapolation is warranted; the variability is too extreme; or if differences in susceptibility have resulted in sensitive subgroups (27) .
Extrapolation to low doses (or exposures) involves determining (or assuming) the shape of the dose-response curve. Establishing a dose-response relationship in a risk assessment might be considered a meta analytic procedure in some instnces. That is, results from different studies mightbe combined to provide a larger sample size or a broader range of dose estimates. The validity of this effort can be enhanced if the same markers are used in different studies or ifdifferent markers have been shown to be correlated (i.e., have construct validity).
The contribution ofmacromolecular adducts to low-dose extrapolation has been the most heralded potential improvement to risk assessment. However, the use ofbiologic markers also can be a source ofconfusion in risk assessments. Most ofthe studies of adducts in humans have not yet demonstrated a clear dose response (1, 29) . This may be due to the wide variability in human response and the current inability to determine true individual exposures. Until the sources ofvariability can be identified and their impact evaluated, the absence or faulty characterization of a dose-response will limit the usefulness ofthis class ofbiologic markers in risk assessments (30, 31) . A potentially major source ofdifferential susceptibility in dose response is the phenotypic variation ofmetabolic parameters (30) . Rarely has this variation been considered in risk assessments.
The effect ofthe choice ofa dose variable on risk estimates can be severe, especially when the pattern of exposure that the esimates are thought to reflect differs from the predominant pattern experienced by a study cohort (32) . The use ofa biological marker ofexposure can help reduce the impact ofusing an ambiguous dose variable because it can more accurately reflect the true dose, even in studies where exposures are observed to have occurred over a wide range. For example, attempts have been made to compare biologically effective doses at high exposures where tumors are observed to low exposure concentrations to determine whether linearity ofthe carcinogenic effect is a valid assumption. Perera (1, 29) has concluded that extensive data on DNA, RNA, and protein binding indicate that macromolecular effects, at the lowest administered doses, generally follow firstorder kinetics (i.e., the rate ofbinding in target organs in vivo is directly proportional to administered dose). Since many carcinogens covalently bind to, and structurally alter DNA, the adducts that are formed are conceptually valid markers ofexposure and possibly of effects. Moreover, the ratio of surrogates for DNA adducts, such as protein adducts, to dose have been shown to be constant over a dose range of 10-' mole/kg to 10 mole/kg (28, 33) . However, as Swenberg (34) 
Examples of Using Biologic Markers in Risk Assessment
The theoretical discussion of marker validity can be applied to risk assessments concerning the fimigant and fuel additive, ethylene dibromide (EDB) and the sterilant and chemical intermediate, ethylene oxide (EtO). Examination ofthe data concerning these two substances and their relationship to the disease process can provide some insight into the question of marker validity. This examination is summarized in Table 1 First, as EDB was absorbed, glutathione production initially decreased, but then recovered. The decrease in the amount of glutathione was associated with the release of2 moles ofbromine for every mole ofglutathione that disappeared. The production offree bromine could be correlated to the airborne exposure concentration, providing an indication ofdose. Further evience was provided to show that the production of S,S'-ethylenebis(glutathione) was saturable (35) . More recent data indicates that when the first molecule of glutathione reacts with EDB, it can form a three-membered sulfur-containing ring that can alkylate DNA to form S-[2-(N7-guanyl) ethyl] glutathione. This alkylation can occur prior to the detoxification reaction ofEDB with the second molecule of glutathione (36) .
These simple data offer some insight into the ovell relationship between EDB exposure and cancer development. The fact that the detoxification pathway is only one of the metabolic pathways indicates that detoxification removes only a portion of the EDB from the system, the remainder being available for reaction with cellular macromolecules. Second, it is possible that EDB does not react with cellular macromolecules until the detoxification pathway has become saturated. If this latter scenario is adopted, then consideration must be given to the existence ofa threshold ofexposure. The first choice, on the other hand, provides support for the concept that there is no dteshold.
Data from other species clearly show that EDB alkylates macromolecules and causes mutations, even at doses well below those that saturate the detoxification patdway, lending support to the theory that there is no threshold for the carcinogenic response. Finally, the production oftumors appears to be related to the cumulative dose (i.e., the exposure concentration multiplied by the duration of exposure).
Ifthe quantitative relationships between exposure concentration, exposure duration, bromine production, adduct formation, gene mutation, and tumor expression were understood, then it would be feasible to use bromine production as a marker ofincreased cancer risk for measures ofbromine prior to saturation ofthe pathway. Does the information about bromine production make sense in the context ofEDB induced cancer? Cainly the information makes sense, at least qualitatively. EDB is used as a fuel additive because its bifunctionality is exploited to remove excess lead from engines (7) . It is that same reative that allows EDB to act as a bifuncional alkylator ofmacromolecules. When the alkylation ofDNA occurs, the cell attempts to repair the damage. Ifthe rate ofrepair is less than the rate ofalkylation, then the damage persists and can lead to a variety ofunwward effects. The observation of enhanced DNA repair rates in mammalian systems supports this mechanism. However, it is important to note that the initial studies on bromine production were conducted at high, int ic doses that saed the metabolic detoxification mechanisms (35) .
Other studies in which animals were exposed to EDB in air at lower concentrations indicated that the rate of metabolism was about 100 times greater than the rate ofabsorption, and thus exposure by inhalation may not pose the same threat as exposure by other routes such as feeding or gavage (35) . Subsequent inhalation studies revealed that inhalation exposures at 10 ppm resulted in tumor development in mammals (35) . Based on pharmacokinetic data, an exposure at 10 ppm would result in the absorption of as little as 0. 4 Ismole EDB/L of air, a concentration well below that shown to saturate detoxification mechanisms (35) . These data indicate that EDB can exert its efect in two ways: by direct action on the tissues that it contacts; and systemically. The latter mechanism indicates that normal detoxification mechanisms do not adequately remove all the EDB, even at relatively low doses. Based on this information, it appears that bromine production, while qualitatively consistent with a possible carcinogenic mechanism, is not a good quantitative marker for EDB-induced carcinogenesis.
In order to obtain more precise information on the relationship between EDB exposure and cancer induction, a marker more sensitive to cellular activity thin bromine release is needed. One such marker might be the formation EDB-DNA adducts, or as appears to be the case for EtO, the formation of hemoglobin adducts.
Hemogloblin Alkylation by Ethylene Oxide
Qualitatively, the data concerning the toxicity ofEtO parallels that of EDB. Each ofthose chemicals is acutely toxic. EtO and EDB can cause mutations in a variety ofplant, bacterial, insect, and manummaian species both in vitro and in vvo, and a number ofinvestigators have clearly established the relationship between EtO exposure and alkylation ofhemoglobin, DNA, and cancer development. For example, Burgnone et al. (37) have demonstrated that the extent ofin vivo hemoglobin alkylation is proportional to the airborne concentration of EtO and the concentration of EtO in blood. Calleman et al. (38, 39) and Ostennan-Golkar (40) have shown that the amount of EtO in blood is proportional to the formation of DNA adducts. In a related study, Yager (41) has demonstrated that the frequency of sister chromatid exchange in peripheral blood of EtO-exposed workers is proportional to cumulative dose (i.e., ppm x hr). Finally, Calleman et al. has shown that there is a relationship between the extent of hemoglobin alkylation by EtO and the number ofrats with tumors following inhalation exposure to EtO (38, 39) . Calleman used those data to esfimate the risk ofdeveloping leukemia as a result of EtO exposure (38, 39) .
It is clear that the formation of alkylated hemoglobin by EtO satisfies the requirements ofa valid biological marker. Though the fonnation ofthat particular marker appears to be an event that occurs independent of those related to EtO-induced cancer development, the formation ofhemoglobin adducts by EtO appears to be a good surrogate for predicting risk. This conclusion is based on the assumption that other mammalian hemoglobin would respond similarly, however, the precise relationships do need to be elucidated. These relationships have been demonstrated in subsequent research (42, 43) .
Conclusion
The framework presented here and in a previous paper (6) may serve as a basis for evaluating the validity ofbiological markers for research and for quantitative risk assessments. At present, there are few valid biological markers that can be used to conduct quantitative risk assessments. Before a marker is useful in risk assessment, it should be shown to have content, criterion, and construct validity, and it should be shown to be reliable. Pilot studies should be performed to establish background levels, the range ofnormal, confounding factors, and optinul collection and analytical techniques. Res h studies using biological markers will need to be ofappropriate sample size and pay attention to the proper selection ofsubjects and the use ofappropriate statistical techniques (5, 6) .
If studies are to be useful in risk assessment, they must be generalizable but, more importantly, they must be internally valid. Hence, to satisfy the ultimate need for generalizability and still be internally valid, studies should involve heterogenous population samples with homogenous subgroupings within the samples. If separate studies are conducted for use in risk assessments, efforts should be made to use similar markers and to pay attention to confounding factors.
Failure to consider the validity ofcomponents ofa risk assessment can lead to erroneous conclusions. For example, in the case ofEDB, ifattempts were made to constr risk arguments based on bromine release data, it might have been concluded that there is a threshold of exposure that must be passed before the carcinogenic process can be initiated. The EtO data, on the other hand, clearly show relationships between airborne exposure concentrations, time, and events at the molecular level that are at least indicative ofa genotoxic and carcinogenic mechanism that is consistent with generally accepted theories ofcarcinogenicity.
